QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 专题：复旦大学上海医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study 期刊论文 LUNG CANCER, 2019, 卷号: 130 作者:  Wu, Yi-Long;  Zhou, Caicun;  Lu, Shun;  Qin, Shukui;  Pan, Hongming 收藏  |  浏览/下载：22/0  |  提交时间：2019/12/05 Asian  Chemotherapy  EGFR  Erlotinib  Non small cell lung cancer   BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2015, 卷号: 33, 期号: 19 作者:  Zhou, Caicun;  Wu, Yi-Long;  Chen, Gongyan;  Liu, Xiaoqing;  Zhu, Yunzhong 收藏  |  浏览/下载：1/0  |  提交时间：2019/12/19 BEYOND: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PHASE III STUDY OF FIRST-LINE CARBOPLATIN/PACLITAXEL (CP) PLUS BEVACIZUMAB (BV) OR PLACEBO (PL) IN CHINESE PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) 会议论文 作者:  Zhou, Caicun;  Chen, Gongyan;  Liu, Xiaoqing;  Zhu, Yunzhong;  Lu, Shun 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/19 NSCLC  Bevacizumab  Chinese patients  first line   FIRST-LINE ERLOTINIB VERSUS CISPLATIN/GEMCITABINE (GP) IN PATIENTS WITH ADVANCED EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC): INTERIM ANALYSES FROM THE PHASE 3, OPEN-LABEL, ENSURE STUDY 会议论文 作者:  Wu, Yi-Long;  Liam, Chong-Kin;  Zhou, Caicun;  Wu, Gang;  Liu, Xiaoqing 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/19 EGFR mutations  Asian patients  erlotinib  NSCLC